Aytu BioPharma, Inc.
AYTU Healthcare Drug Manufacturers Specialty & Generic
Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025. In the quarter to June 2026, revenue grew 6.42%, EPS grew 100.0%, free cash flow grew 57.7% and total debt fell 21.9%, each against the same quarter a year earlier.
Follow AYTU
Aytu BioPharma, Inc. (AYTU) P/E ratio
Aytu BioPharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 13.0× (May 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RMTI Rockwell Medical, Inc. compare | n/m |
| AYTU Aytu BioPharma, Inc. | n/m |
| TXMD TherapeuticsMD, Inc. compare | n/m |
| IXHL Incannex Healthcare Inc. compare | n/m |
| UPC Universe Pharmaceuticals INC compare | n/m |
| CPHI China Pharma Holdings, Inc. compare | n/m |
| BGXXQ Bright Green Corporation compare | n/m |
| BFRI Biofrontera Inc. compare | n/m |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | 0.2× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)